Alembic Pharmaceuticals Quarterly Results for Trading Insights
In Mar 2026, Alembic Pharmaceuticals (APLLTD) reported revenue ₹1,874 Cr and net profit ₹202 Cr — revenue +5.0% YoY. For annual financials, live price and key ratios, visit Alembic Pharmaceuticals screener.
APLLTD Quarterly Results — Revenue, Profit & EPS Highlights
Alembic Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Check Alembic Pharmaceuticals marketcap in USD to track the company's total market size over time.
- Revenue of ₹1,874 Cr in Mar 2026 (-13.4% vs Jun 2026, +5.0% vs Mar 2025)
- Net Profit of ₹202 Cr in Mar 2026 (+17.4% vs Jun 2026, +28.7% vs Mar 2025)
- EBITDA of ₹230 Cr in Mar 2026 (-33.7% vs Jun 2026)
- Operating Margin of 11.0% in Mar 2026 (-4.0pp vs Jun 2026)
- Earnings Per Share of ₹10.31 in Mar 2026 (+17.2% vs Jun 2026)
Alembic Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
APLLTD quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1,874 | 2,165 | 1,919 | 1,784 | 1,717 | -13.4% | 5.0% |
| Net Profit (₹ Cr) | 202 | 172 | 184 | 157 | 154 | - | - |
| EBITDA (₹ Cr) | 230 | 347 | 324 | 286 | 287 | - | - |
| EPS (₹) | 10.31 | 8.80 | 9.40 | 7.98 | 7.85 | - | - |
| Operating Margin (%) | 11.0% | 15.0% | 17.0% | 15.0% | 16.0% | - | - |
APLLTD Share Price Trend — 1-Year Movement Across Quarterly Results
Alembic Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse APLLTD FII DII holdings to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
APLLTD vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Alembic Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹463,071.60 Cr | 1902.4 | 15,018 | 2,710 | -5.6% | - | 18.0% | 168.4 |
|
Divis Laboratories
Mar 2026 |
₹225,157.18 Cr | 8597.0 | 2,986 | 751 | -5.0% | - | 25.2% | 303.7 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4896.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 425.4 |
|
Cipla
Mar 2026 |
₹115,699.61 Cr | 1432.2 | 6,612 | 543 | -9.3% | - | 8.2% | 208.5 |
|
Zydus Life Science
Mar 2026 |
₹113,855.38 Cr | 1120.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 88.5 |
All amounts in ₹ Crores